What is the connection between asthma and diabetes. How do these conditions affect each other. What are the common risk factors for both asthma and diabetes. How can patients manage both conditions effectively.

Understanding Asthma: Types, Causes, and Prevalence

Asthma is a chronic respiratory condition characterized by inflammation and narrowing of the airways. It affects approximately 1 in 13 people in the United States, making it a significant public health concern. While asthma can develop at any age, it often begins in childhood and may persist or recur later in life.

There are several types of asthma, each with distinct triggers and characteristics:

• Allergic asthma (60% of cases)
• Non-allergic asthma (10-33% of cases)
• Exercise-induced asthma
• Occupational asthma (up to 15% of cases)
• Adult-onset asthma

Allergic asthma is the most common type, triggered by allergens such as pollen, dust mites, and pet dander. Non-allergic asthma, on the other hand, can be triggered by factors like respiratory infections, certain medications, or environmental conditions.

The Intriguing Link Between Asthma and Diabetes

Recent studies have uncovered a fascinating connection between asthma and diabetes. Research involving 78,000 adults with type 1 and type 2 diabetes revealed a higher prevalence of asthma among diabetic patients compared to those without diabetes. This association raises important questions about the underlying mechanisms connecting these two seemingly unrelated conditions.

Why is there a connection between asthma and diabetes? Several factors may contribute to this relationship:

1. Shared risk factors, such as obesity
2. Increased insulin resistance and metabolic syndrome in diabetic patients
3. Complex interactions between the immune system and the environment
4. The “hygiene hypothesis” and its potential impact on both conditions

Furthermore, a study focusing on children and young adults with diabetes found that they may be at higher risk of developing asthma. This connection can complicate diabetes management, as asthma can make blood sugar control more challenging.

Common Risk Factors for Asthma and Diabetes

Understanding the shared risk factors for asthma and diabetes is crucial for effective prevention and management strategies. Some of the key risk factors include:

• Obesity: A significant contributor to both conditions
• Genetic predisposition: Family history can increase risk for both asthma and diabetes
• Environmental factors: Air pollution and exposure to certain chemicals
• Lifestyle choices: Sedentary behavior and poor diet
• Immune system dysregulation: Altered immune responses may play a role in both conditions

By addressing these common risk factors, individuals may be able to reduce their likelihood of developing either condition or better manage existing symptoms.

Recognizing Asthma Symptoms and Complications

Identifying asthma symptoms early is crucial for proper management and preventing complications. Common symptoms of asthma include:

• Wheezing
• Shortness of breath
• Chest tightness
• Persistent coughing, especially at night
• Difficulty performing daily activities

If left untreated or poorly managed, asthma can lead to various complications:

1. Reduced quality of life and limited physical activities
2. Increased risk of respiratory infections
3. Sleep disturbances and fatigue
4. Permanent narrowing of airways (airway remodeling)
5. Increased healthcare utilization and costs

For individuals with both asthma and diabetes, these complications can be even more challenging to manage, highlighting the importance of a comprehensive treatment approach.

Effective Strategies for Managing Asthma

Managing asthma effectively requires a multifaceted approach. Here are some key strategies to help control asthma symptoms:

1. Identify and avoid triggers: Keep a symptom diary to track potential triggers
2. Use prescribed medications as directed: This may include both long-term control and quick-relief medications
3. Develop an asthma action plan with your healthcare provider
4. Monitor lung function regularly using a peak flow meter
5. Maintain a healthy lifestyle: Exercise regularly and maintain a balanced diet
6. Get vaccinated against influenza and pneumococcal disease
7. Practice stress-reduction techniques, such as deep breathing exercises

How can you prevent asthma exacerbations? In addition to the strategies mentioned above, consider the following tips:

• Keep your living environment clean and free of allergens
• Use an air purifier to reduce indoor air pollutants
• Quit smoking and avoid exposure to secondhand smoke
• Wear a scarf or mask in cold weather to warm the air you breathe
• Be prepared for changes in weather or seasonal allergies

Holistic Approach to Managing Diabetes and Asthma

For individuals living with both diabetes and asthma, a comprehensive management plan is essential. Here are some tips for effectively controlling both conditions:

1. Coordinate care between your diabetes and asthma specialists
2. Monitor blood sugar levels closely, especially during asthma exacerbations
3. Maintain a healthy weight through proper nutrition and regular exercise
4. Stay consistent with medication regimens for both conditions
5. Manage stress levels through relaxation techniques or counseling
6. Attend regular check-ups and screenings for both conditions
7. Educate yourself about the potential interactions between asthma and diabetes medications

What role does exercise play in managing both asthma and diabetes? Regular physical activity can help improve lung function, control blood sugar levels, and maintain a healthy weight. However, it’s important to work with your healthcare team to develop an exercise plan that’s safe and effective for your individual needs.

The Impact of Obesity on Asthma and Diabetes

Obesity is a significant risk factor for both asthma and diabetes, and its prevalence among individuals with these conditions is a growing concern. Here’s how obesity impacts these conditions:

• Increases inflammation throughout the body
• Reduces lung function and makes breathing more difficult
• Contributes to insulin resistance and poor blood sugar control
• Makes it harder to engage in physical activity
• Can lead to sleep apnea, which may worsen both asthma and diabetes

How can weight loss benefit individuals with asthma and diabetes? Losing excess weight can improve lung function, reduce asthma symptoms, enhance insulin sensitivity, and lower blood sugar levels. Even modest weight loss can lead to significant improvements in both conditions.

Strategies for Achieving and Maintaining a Healthy Weight

To support weight loss efforts and improve overall health, consider the following strategies:

1. Adopt a balanced, nutrient-rich diet
2. Practice portion control and mindful eating
3. Engage in regular physical activity, starting gradually and increasing intensity over time
4. Seek support from a registered dietitian or weight loss specialist
5. Consider joining a support group for motivation and accountability
6. Address emotional eating and develop healthy coping mechanisms
7. Get adequate sleep, as poor sleep can contribute to weight gain and worsen both asthma and diabetes

The Role of Inflammation in Asthma and Diabetes

Inflammation plays a crucial role in both asthma and diabetes, contributing to the development and progression of these conditions. Understanding the inflammatory processes involved can help in developing more targeted treatment approaches.

Asthma and Inflammation

In asthma, inflammation in the airways leads to:

• Swelling and narrowing of the bronchial tubes
• Increased mucus production
• Hyperresponsiveness to triggers
• Remodeling of the airways over time

Diabetes and Inflammation

In diabetes, chronic low-grade inflammation contributes to:

• Insulin resistance
• Beta-cell dysfunction
• Complications affecting various organs
• Increased risk of cardiovascular disease

How does addressing inflammation benefit both conditions? By targeting inflammation through medications, lifestyle changes, and dietary interventions, it may be possible to improve outcomes for both asthma and diabetes simultaneously.

The Importance of Personalized Treatment Plans

Given the complex relationship between asthma and diabetes, as well as individual variations in symptoms and triggers, personalized treatment plans are essential for optimal management. Here’s why individualized care is crucial:

• Accounts for unique risk factors and genetic predispositions
• Addresses specific triggers and symptoms
• Considers potential drug interactions and side effects
• Adapts to changing needs over time
• Improves treatment adherence and outcomes

What elements should be included in a personalized treatment plan? A comprehensive plan should address medication management, lifestyle modifications, regular monitoring, and strategies for managing comorbidities.

Components of a Personalized Treatment Plan

1. Detailed medical history and assessment of current symptoms
2. Identification of specific triggers and risk factors
3. Tailored medication regimens for both asthma and diabetes
4. Individualized action plans for managing exacerbations
5. Nutrition and exercise recommendations
6. Regular follow-up appointments and adjustments as needed
7. Education on self-management techniques

Emerging Research and Future Directions

As our understanding of the relationship between asthma and diabetes continues to evolve, researchers are exploring new avenues for treatment and prevention. Some promising areas of investigation include:

• The role of the gut microbiome in both conditions
• Novel anti-inflammatory therapies targeting shared pathways
• Personalized medicine approaches using genetic and biomarker data
• The potential of immunomodulatory treatments
• The impact of environmental factors and climate change on disease prevalence

How might these research directions impact patient care in the future? As new discoveries are made, we may see more targeted therapies, improved prevention strategies, and better tools for managing both asthma and diabetes simultaneously.

Potential Breakthroughs on the Horizon

Some exciting developments in asthma and diabetes research include:

1. Biologic therapies targeting specific inflammatory pathways
2. Artificial intelligence-driven predictive models for disease management
3. Gene therapy approaches for both conditions
4. Novel drug delivery systems for improved medication efficacy
5. Wearable technology for real-time monitoring and intervention

As research progresses, individuals living with asthma and diabetes can look forward to more effective, personalized treatment options and improved quality of life.

The Role of Patient Education and Self-Management

Empowering patients with knowledge and self-management skills is crucial for effectively managing both asthma and diabetes. Proper education can lead to better treatment adherence, improved outcomes, and a higher quality of life. Here are some key aspects of patient education and self-management:

• Understanding the nature of both conditions and their potential interactions
• Recognizing symptoms and triggers
• Proper use of medications and devices (e.g., inhalers, glucose meters)
• Developing and following action plans for exacerbations
• Implementing lifestyle modifications for better health
• Regular self-monitoring and record-keeping

How can healthcare providers support patient education and self-management? Providers can offer structured education programs, provide written materials, demonstrate proper techniques, and encourage patients to actively participate in their care.

Tools and Resources for Self-Management

Several tools and resources can aid in the self-management of asthma and diabetes:

1. Smartphone apps for symptom tracking and medication reminders
2. Peak flow meters and spirometers for monitoring lung function
3. Continuous glucose monitoring systems for diabetes management
4. Online support groups and forums for peer support
5. Educational websites and videos from reputable health organizations
6. Telemedicine platforms for remote consultations with healthcare providers
7. Wearable devices for tracking physical activity and vital signs

By utilizing these tools and resources, patients can take a more active role in managing their conditions and collaborating effectively with their healthcare team.

The Importance of a Multidisciplinary Approach

Managing the complex interplay between asthma and diabetes often requires a multidisciplinary approach. Collaboration among various healthcare professionals can ensure comprehensive care and address all aspects of a patient’s health. Key members of a multidisciplinary team may include:

• Primary care physician
• Pulmonologist or asthma specialist
• Endocrinologist or diabetes specialist
• Allergist/Immunologist
• Registered dietitian
• Certified diabetes educator
• Respiratory therapist
• Mental health professional

How does a multidisciplinary approach benefit patients with asthma and diabetes? This collaborative model ensures that all aspects of care are coordinated, potential interactions between treatments are considered, and patients receive comprehensive support for managing both conditions.

Benefits of Integrated Care

An integrated, multidisciplinary approach to managing asthma and diabetes offers several advantages:

1. Improved coordination of care and communication among healthcare providers
2. More comprehensive treatment plans addressing all aspects of health
3. Reduced risk of medication interactions and adverse effects
4. Enhanced patient education and self-management support
5. Better management of comorbidities and complications
6. Potential cost savings through more efficient care delivery
7. Improved patient satisfaction and quality of life

By embracing a multidisciplinary approach, healthcare systems can provide more effective, patient-centered care for individuals living with both asthma and diabetes.

What’s The Connection Between Diabetes And Asthma?

Content

• Overview
• What is asthma?
• What is the connection between diabetes and asthma?
• What are the risk factors related to both asthma and diabetes?
• Symptoms and complications of asthma
• What are the complications of asthma?
• How to manage asthma?
• What should I do to avoid worsening my asthma?
• Tips for controlling diabetes and asthma
• The lowdown

Have you considered clinical trials for Diabetes?

We make it easy for you to participate in a clinical trial for Diabetes, and get access to the latest treatments not yet widely available – and be a part of finding a cure.

Check your eligibility

Asthma is a chronic condition affecting the lungs. Inflammation and swelling narrow your airways intermittently, making it difficult for air to flow in and out of your lungs. Your airways become hyperreactive to things in the environment, including smoke, dust, chemicals, and pet dander.  

When you breathe in these triggers, the airways’ interior may swell, narrowing the space for air to flow through. The muscles surrounding your airways may tighten, making breathing harder. 

Asthma affects about 1 out of 13 people¹ in the U.S. It can start at any age, but most people develop asthma during childhood. It is the most common chronic disease in children in resource-rich countries.

Some children may outgrow asthma as they grow older, but it may reoccur later in life. Other people develop asthma for the first time during adulthood. 

Most common types of asthma

Allergic asthma

Allergic asthma affects about 60% of patients with asthma in the U.S. Common allergens include pollen, dust mites, cockroaches, irritants in the environment such as smoke, mold spores, perfumes, and foods such as eggs and milk. 

Allergic asthma can also be seasonal, so you’ll experience symptom flare-ups at particular times of the year or in certain conditions. Your symptoms may appear or worsen during winter when there are more flu viruses around or during spring when there is pollen in the environment. 

Non-allergic asthma

Non-allergic asthma is less common than allergic asthma and accounts for about 10–33%² of asthma cases. Allergens do not trigger this type of asthma. Respiratory infections such as flu, medications such as aspirin, or environmental factors such as cold, stress, and humidity can cause non-allergic asthma.

Exercise-induced asthma

Exercise-induced asthma happens when symptoms appear or worsen during or immediately after strenuous activity. Shortness of breath is common for many after strenuous exercise.

However, the shortness of breath you experience with exercise-induced asthma can occur alongside other symptoms such as wheezing, coughing, and chest pain. 

Occupational asthma

If you have occupational asthma, your symptoms may worsen while working. You may notice improvements when they are off duty. Occupational asthma accounts for up to 15% of asthma cases in the U.S. due to exposure to insecticides, aerosols, or other harmful substances.

Some people may experience symptoms within 24 hours, while others experience symptoms after months or even years. 

Adult-onset asthma

Asthma usually starts in childhood. However, it may occur for the first time during adulthood in some people. This type of asthma is called late-onset or adult-onset asthma.

Risk factors of adult-onset asthma include female hormones, smoking, stressful life events, or even occupational asthma. 

Most studies³ demonstrate a connection between diabetes and asthma. For example, one study found that asthma prevalence was higher in patients with diabetes than in those without it. The study looked at 78,000 adults with type 1 and 2 diabetes.

Although some studies have not demonstrated such associations, this may be related to population-level interactions between the immune system and the environment.  

Another study⁴ reveals that children and young adults who have diabetes may be at higher risk of developing asthma. This may affect their ability to manage their diabetes, as asthma makes it harder to control blood sugar.

72% of people in the study who were treating their asthma had good glycemic control, whereas 31% who left their condition untreated had poor glycemic control. 

Obesity is a risk factor for both diabetes and asthma. The prevalence of obesity among people with type 2 diabetes is one of the potential reasons for a higher incidence of asthma. Additionally, people with diabetes have increased insulin resistance and metabolic syndrome, two conditions that can increase the risk of asthma. 

The intricate relationship between our immune system and the environment may be another factor behind asthma and diabetes. The “hygiene hypothesis” may explain the increased risk for both.

Studies proposed that childhood exposure to infections and certain germs can help the immune system develop, but the hygiene hypothesis is contentious.

Wheezing is the whistling or squealing sound that occurs during expiration. It is the most common symptom of asthma. However, asthma has other symptoms, including:

• Shortness of breath

• Rapid breathing

• Coughing, especially during exercise, when laughing, or at night

• Difficulty speaking

• Fatigue

• Chest tightness

• Anxiousness or panic

• Difficulty sleeping

Even when you manage asthma well, occasional flare-up symptoms such as coughing, fatigue, throat clearing, chest tightness or pain, and trouble sleeping may still occur. Using quick-acting treatments such as a rescue inhaler can improve the situation, but you may need medical attention if the symptoms persist or worsen.

Some symptoms indicate an asthma emergency, and you should seek medical intervention if you experience them. These symptoms include: 

• Gasping for air

• Dizziness

• Pale or blue lips or fingernails

• Severe breathing difficulty

• Difficulty talking or walking

Proper asthma management is important to avoid complications such as:

• Constant asthma flare-ups that make you leave work or school 

• Respiratory failure. This often occurs if the narrowing and thickening of bronchial tubes become permanent

• Irreversible airway obstruction from a decline in lung function and persistent inflammation. This obstruction resembles chronic obstructive pulmonary disease (COPD) and may progressively worsen, limiting your activity.

Medication

Asthma medication falls into two categories: Preventers and relievers. Relievers help when symptoms occur, while preventers reduce the sensitivity of the airways to triggers, reducing inflammation. 

Reliever medication 

Reliever medication opens the airways quickly. You take it for immediate relief when experiencing an asthma flare-up or emergency. However, you should use this medication carefully because overuse can lead to side effects such as a rapid heart rate and tremors. 

Excluding the use of reliever medication before exercise, you should see your healthcare provider to review your asthma if you need to use a reliever more than twice a week.  

Preventer medication

Preventer medication reduces your airways’ sensitivity, thus reducing swelling and inflammation. You should take your preventer medication as prescribed over the long term to effectively reduce the risk or severity of any flare-ups. 

Inhaled corticosteroids are among the most commonly used preventer medication. It goes straight to the lungs where it’s needed, with a low risk of systemic side effects. Even a low dose of this medication can control symptoms in most patients, especially adults.

Children who need a regular preventer medication can use inhaled corticosteroids or a non-steroid preventer tablet. Your doctor can advise the best type of medication for your child depending on their age, symptoms, and how easy it will be to administer correctly. 

Combination therapy

If you use a preventer medication but you still experience regular asthma symptoms, you may need to boost your medication. You may need a combination therapy where you take a second medicine while using an inhaled corticosteroid. However, your prescription should be a combination that works for you or your child at the lowest effective dose. 

Inhaler devices for asthma medication

Inhaler devices make asthma medication work more effectively. Your doctor can help you decide on the best inhaler device, but the three main types available include:

1. Metered-dose inhaler (puffer)

This aerosol canister releases the medication as a fine mist as you press it down. If you use this canister, ensure you always shake it before use. You should always place a spacer with your puffer. 

2. Autohaler

This aerosol canister releases the mist automatically when you begin to breathe in via the mouthpiece. It is good for children and people who struggle coordinating a puffer. 

3. Dry-powder inhalers 

This inhaler device contains the medication as a dry powder instead of the liquid in the aerosol inhalers. It requires you to take a deep breath to release the medicine into the lungs. Therefore, it might be difficult to use when experiencing shortness of breath. 

Additional mechanisms for drug delivery

If you have a severe asthmatic case, you may need additional types of medication delivery. The doctor may prescribe the following additional devices to assist with medication delivery:

1. Spacers

This device resembles a clear tube, allowing more medication to reach the lungs and reducing potential side effects. You attach it to the metered-dose inhaler to ease your inhalation of the medicine.

Fire a single puff of the medication into the spacer, take a slow deep breath, and hold your breath for about five seconds or as long as you feel comfortable. If you are administering the medication to a child, let them take four breaths in and out before you fire the next puff into the spacer. 

2. Nebulizers 

You can also opt for a nebulizer which serves the same function as a puffer with a spacer. Nebulizers were popular among asthma patients in the past. They are still available because they are cheaper and easier to use while reducing the side effects of the medication. If you wish to switch to a nebulizer, speak to your doctor. 

1. Identify asthma triggers

Identify your asthma triggers and find ways to avoid them. Triggers include cold air, stress, smoke, molds, exercise, and air pollution. Keep track of all times you experience asthma symptoms and identify the emotional and environmental factors around you. This can help you identify what might have caused an asthma flare-up. You can also talk to your healthcare provider about allergen tests. 

If you’re sensitive to smoke, stay away from the trigger by limiting your exposure to any source of smoke, such as fireworks, incense, and tobacco. If you smoke, seek medical advice on how to quit. 

Avoid getting close to people with flu or cold since catching it can worsen your symptoms. If you have exercise-induced asthma, you can prevent asthma attacks by using an inhaler before the exercise or by breathing through a loose-fitting scarf or mask if exercising in cold, dry conditions.

2. Get flu vaccinations

Contracting the flu can worsen asthma symptoms. You can ensure your safety by getting a flu shot every year for protection against the virus.

3. Go for immunotherapy allergy shot

Allergy shots can prevent allergy symptoms and stop your condition from worsening. The idea is that if your body gets used to the allergen, it’ll respond less when exposed.

4. Take your asthma medications as prescribed

Asthma medications aim to prevent symptoms and attacks. You should use your prescribed medication even when you don’t have symptoms. They keep asthma under control by easing inflammation in the airways, reducing potential flare-ups.  

Controlling diabetes and asthma may require you to manage each condition separately. You can control diabetes by eating a healthy diet, exercising regularly, weight management, and taking any prescribed diabetes medication. Weight management avoids obesity, a risk factor for asthma. 

Controlling asthma involves avoiding allergens and sticking to your medication even when you don’t see symptoms.  

If you have diabetes and asthma, both conditions benefit from medications. Metformin, a drug that treats type 2 diabetes, may improve asthma symptoms. It may also reduce the number of asthma-related emergency room visits if you have concurrent asthma and diabetes.

Other studies show that GLP-1 receptor agonists, another group of diabetes medications, may benefit patients with asthma. These medications aid blood glucose control, may improve asthma symptoms, and reduce inflammation in the lungs and airways. 

If you have asthma, you can live a healthy and active life provided you control and manage your symptoms. As there is a connection between diabetes and asthma, managing diabetes can improve your asthma symptoms if you have both conditions.

For example, controlling your weight can reduce obesity, a risk factor for diabetes and asthma. 

Association between Asthma and Type 2 Diabetes Mellitus: Mechanisms and Impact on Asthma Control—A Literature Review

1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Fontana-on-Geneva Lake, WI, USA: Global Initiative for Asthma; 2018. https://ginasthma.org/wp-content/uploads/2019/01/2018-GINA.pdf. [Google Scholar]

2. Shu C. J., Benoist C., Mathis D. The immune system’s involvement in obesity-driven type 2 diabetes. Seminars in Immunology. 2012;24(6):436–442. doi: 10.1016/j.smim.2012.12.001. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

3. Perez M. K., Piedimonte G. Metabolic asthma: is there a link between obesity, diabetes and asthma? Immunology and Allergy Clinics of North America. 2014;34(4):777–784. doi: 10.1016/j.iac.2014.07.002. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

4. Salles C., Terse-Ramos R., Souza-Machado A., Cruz A. A. Obstructive sleep apnea and asthma. Jornal Brasileiro de Pneumologia. 2013;39(5):604–612. doi: 10.1590/s1806-37132013000500011. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

5. Zammit C., Liddicoat H., Moonsie I., Makker H. Obesity and respiratory diseases. International Journal of General Medicine. 2010;3:335–343. doi: 10.2147/IJGM.S11926. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

6. Su X., Ren Y., Li M., Zhao X., Kong L., Kang J. Prevalence of comorbidities in asthma and nonasthma patients. Medicine. 2016;95(22):p. e3459. doi: 10.1097/md.0000000000003459. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

7. Adeyeye O. O., Ogbera A. O., Ogunleye O. O., et al. Understanding asthma and the metabolic syndrome—a Nigerian report. International Archives of Medicine. 2012;5(1):p. 20. doi: 10.1186/1755-7682-5-20. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

8. Global Asthma Network. The Global Asthma Report 2018. Auckland, New Zealand: Global Asthma Network; 2018. http://www.globalasthmanetwork.org/publications/Global_Asthma_Report_2014.pdf. [Google Scholar]

9. International Diabetes Federation. IDF Diabetes Atlas. 9a. Brussels, Belgium: International Diabetes Federation; 2020. https://www.diabetesatlas.org/upload/resources/2019/IDF_Atlas_9th_Edition_2019.pdf. [Google Scholar]

10. World Health Organization. WHO. Obesity and Overweight. Fact Sheets N° 311. Geneva, Switzerland: World Health Organization; 2016. http://http://www.who.int/mediacentre/factsheets/fs311/en/l. [Google Scholar]

11. http://www.brasil.gov.br/saude/2015/01/asma-atinge-6-4-milhoes-de-brasileiros. Brasil. Ministério da Saúde. Portal da Saúde. Brasília: Ministério de Saúde. Asma atinge 6,4 milhões de brasileiros, 2019,

12. Brasil. Ministério da Saúde. Vigitel Brasil 2018—Vigilância de fatores de risco e proteção para doenças crônicas por inquérito telefônico: estimativas sobre frequência e distribuição sociodemográfica de fatores de risco e proteção para doenças crônicas nas capitais dos 26 estados brasileiros e no Distrito Federal em 2018—Brasília: DF, 2019.

13. Papi A., Brightling C., Pedersen S. E., Reddel H. K. Asthma. The Lancet. 2018;391(10122):783–800. doi: 10.1016/s0140-6736(17)33311-1. [PubMed] [CrossRef] [Google Scholar]

14. Mueller N. T., Koh W.-P., Odegaard A. O., Gross M. D., Yuan J.-M., Pereira M. A. Asthma and the risk of type 2 diabetes in the Singapore Chinese Health Study. Diabetes Research and Clinical Practice. 2013;99(2):192–199. doi: 10.1016/j.diabres.2012.11.019. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

15. Song Y., Klevak A., Manson J. E., Buring J. E., Liu S. Asthma, chronic obstructive pulmonary disease, and type 2 diabetes in the Women’s Health Study. Diabetes Research and Clinical Practice. 2010;90(3):365–371. doi: 10.1016/j.diabres.2010.09.010. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

16. Baek J. Y., Lee S. E., Han K., Koh E. H. Association between diabetes and asthma. Annals of Allergy, Asthma & Immunology. 2018;121(6):699–703. doi: 10. 1016/j.anai.2018.08.008. [PubMed] [CrossRef] [Google Scholar]

17. Rana J. S., Mittleman M. A., Sheikh J., et al. Chronic obstructive pulmonary disease, asthma, and risk of type 2 diabetes in women. Diabetes Care. 2004;27(10):2478–2484. doi: 10.2337/diacare.27.10.2478. [PubMed] [CrossRef] [Google Scholar]

18. Gershon A. S., Guan J., Wang C., Victo, Charles J. To T. Describing and quantifying asthma comorbidty: a population study. PLoS One. 2012;7 doi: 10.1371/journal.pone.0034967.e34967 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

19. Yun H. D., Knoebel E., Fenta Y., et al. Asthma and proinflammatory conditions: a population-based retrospective matched cohort study. Mayo Clinic Proceedings. 2012;87(10):953–960. doi: 10.1016/j.mayocp.2012.05.020. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

20. Wytrychowski K., Obojski A., Hans-Wytrychowska A. The influence of insulin therapy on the course of acute exacerbation of bronchial asthma. Advances in Experimental Medicine and Biology. 2016;884:45–51. doi: 10.1007/5584_2015_175. [PubMed] [CrossRef] [Google Scholar]

21. Klein O. L., Aviles-Santa L., Cai J., et al. Hispanics/latinos with type 2 diabetes have functional and symptomatic pulmonary impairment mirroring kidney microangiopathy: findings from the hispanic community health study/study of Latinos (HCHS/SOL) Diabetes Care. 2016;39(11):2051–2057. doi: 10.2337/dc16-1170. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

22. Tesse R., Schieck M., Kabesch M. Asthma and endocrine disorders: shared mechanisms and genetic pleiotropy. Molecular and Cellular Endocrinology. 2011;333(2):103–111. doi: 10.1016/j.mce.2010.11.032. [PubMed] [CrossRef] [Google Scholar]

23. Sweeney J., Patterson C. C., Menzies-Gow A., et al. Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the optimum patient care research database and the British thoracic difficult asthma registry. Thorax. 2016;71(4):339–346. doi: 10.1136/thoraxjnl-2015-207630. [PubMed] [CrossRef] [Google Scholar]

24. Rafacho A., Ortsäter H., Nadal A., Quesada I. Glucocorticoid treatment and endocrine pancreas function: implications for glucose homeostasis, insulin resistance and diabetes. Journal of Endocrinology. 2014;223(3):R49–R62. doi: 10.1530/joe-14-0373. [PubMed] [CrossRef] [Google Scholar]

25. Ernst P., Suissa S. Systemic effects of inhaled corticosteroids. Current Opinion in Pulmonary Medicine. 2011;18:85–89. [PubMed] [Google Scholar]

26. Moher D., Liberati A., Tetzlaff J., Altman D. G., The PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine. 2009;6(7) doi: 10.1371/journal.pmed.1000097.e100009 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

27. Rodbard H. W., Bays H. E., Gavin J. R., et al. Rate and risk predictors for development of self-reported type-2 diabetes mellitus over a 5-year period: the SHIELD study. International Journal of Clinical Practice. 2012;66(7):684–691. doi: 10.1111/j.1742-1241.2012.02952.x. [PubMed] [CrossRef] [Google Scholar]

28. Thomsen S. F., Duffy D. L., Kyvik K. O., Skytthe A., Backer V. Risk of asthma in adult twins with type 2 diabetes and increased body mass index. Allergy. 2011;66(4):562–568. doi: 10.1111/j.1398-9995.2010.02504.x. [PubMed] [CrossRef] [Google Scholar]

29. Hashemzadeh M., Movahed M. R. The occurrence of asthma in hospitalized patients with type 2 diabetes mellitus. Internal Medicine Journal. 2009;39(10):699–701. doi: 10.1111/j.1445-5994.2009.01976.x. [PubMed] [CrossRef] [Google Scholar]

30. Gulcan E., Bulut I., Toker A., Gulcan A. Evaluation of glucose tolerance status in patients with asthma bronchiale. Journal of Asthma. 2009;46(2):207–209. doi: 10.1080/02770900802627302. [PubMed] [CrossRef] [Google Scholar]

31. Verbovoy A. F., Kosareva O. V., Akhmerova R. I. Leptin, resistin, and hormonal and metabolic parameters in women with type 2 diabetes and in those with its concurrence with asthma. Terapevticheskii Arkhiv. 2014;87:37–41. [PubMed] [Google Scholar]

32. Koskela H. O., Salonen P. H., Niskanen L. Hyperglycaemia during exacerbations of asthma and chronic obstructive pulmonary disease. The Clinical Respiratory Journal. 2013;7(4):382–389. doi: 10.1111/crj.12020. [PubMed] [CrossRef] [Google Scholar]

33. Suissa S., Kezouh A., Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. The American Journal of Medicine. 2010;123(11):1001–1006. doi: 10.1016/j.amjmed.2010.06.019. [PubMed] [CrossRef] [Google Scholar]

34. Faul J. L., Wilson S. R., Chu J. W., Canfield J., Kuschner W. G. The effect of an inhaled corticosteroid on glucose control in type 2 diabetes. Clinical Medicine & Research. 2009;7(1-2):14–20. doi: 10.3121/cmr.2009.824. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

35. Kankaanranta H., Kauppi P., Tuomist L. E., Ilmarinen P. Emerging comorbidities in adult asthma: risks, clinical associations, and mechanisms. Mediators of Inflammation. 2016;2016:23. doi: 10.1155/2016/3690628.3690628 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

36. Singh S., Prakash Y. S., Linneberg A., Agrawal A. Insulin and the lung: connecting asthma na metabolic syndrome. Journal of Allergy. 2013;1(20):37.627384 [Google Scholar]

37. Yeryomenko G. V., Bezditko T. V. The treatment of patients with asthma and comorbidity. Medicni Perspektivi (Medical Perspectives) 2018;23(1(part 1)):50–59. doi: 10.26641/2307-0404.2018.1(part1).127209. [CrossRef] [Google Scholar]

38. Li C.-Y., Erickson S. R., Wu C.-H. Metformin use and asthma outcomes among patients with concurrent asthma and diabetes. Respirology. 2016;21(7):1210–1218. doi: 10.1111/resp.12818. [PubMed] [CrossRef] [Google Scholar]

39. Koskela H. O., Salonen P. H., Romppanen J., Niskanen L. A history of diabetes but not hyperglycaemia during exacerbation of obstructive lung disease has impact on long-term mortality: a prospective, observational cohort study. BMJ Open. 2015;29(5)e006794 [PMC free article] [PubMed] [Google Scholar]

40. Wouters E. F. M., Reynaert N. L., Dentener M. A., Vernooy J. H. J. Systemic and local inflammation in asthma and chronic obstructive pulmonary disease: is there a connection? Proceedings of the American Thoracic Society. 2009;6(8):638–647. doi: 10.1513/pats.200907-073dp. [PubMed] [CrossRef] [Google Scholar]

41. Wellen K. E., Hotamisligil G. S., Hotamisligil G. S. Inflammation, stress, and diabetes. Journal of Clinical Investigation. 2005;115(5):1111–1119. doi: 10.1172/jci25102. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

42. Lee C. C., Liu S. Role of inflammatory cytokines in type 2 diabetes. Journal of Periodontology. 2008;79:1527–1534. [PubMed] [Google Scholar]

43. Berg A. H., Scherer P. E. Adipose tissue, inflammation, and cardiovascular disease. Circulation Research. 2005;96(9):939–949. doi: 10.1161/01.res.0000163635.62927.34. [PubMed] [CrossRef] [Google Scholar]

44. Bastard J. P., Maachi M., Lagathu C., et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. European Cytokine Network. 2006;17(1):4–12. [PubMed] [Google Scholar]

45. Chesné J., Braza F., Mahay G., Brouard S., Aronica M., Magnan A. IL-17 in severe asthma. Where do we stand? American Journal of Respiratory and Critical Care Medicine. 2014;190(10):1094–1101. doi: 10.1164/rccm.201405-0859pp. [PubMed] [CrossRef] [Google Scholar]

46. Ramalho R., Guimarães C. Papel do tecido adiposo e dos macrófagos no estado de inflamação crónica associada à obesidade: implicações Clínicas. Acta medica portuguesa. 2008;21:489–496. [PubMed] [Google Scholar]

47. Singh S., Bodas M., Bhatraju N. K., et al. Hyperinsulinemia adversely affects lung structure and function. American Journal of Physiology-Lung Cellular and Molecular Physiology. 2016;310(9):L837–L845. doi: 10. 1152/ajplung.00091.2015. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

48. Thuesen B. H., Husemoen L. L. N., Hersoug L.-G., Pisinger C., Linneberg A. Insulin resistance as a predictor of incident asthma-like symptoms in adults. Clinical & Experimental Allergy. 2009;39(5):700–707. doi: 10.1111/j.1365-2222.2008.03197.x. [PubMed] [CrossRef] [Google Scholar]

49. Agrawal A., Prakash Y. S. Obesity, metabolic syndrome, and airway disease. Immunology and Allergy Clinics of North America. 2014;34(4):785–796. doi: 10.1016/j.iac.2014.07.004. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

50. Lugogo N. L., Bappanad D., Kraft M. Obesity, metabolic dysregulation and oxidative stress in asthma. Biochimica et Biophysica Acta (BBA)—General Subjects. 2011;1810(11):1120–1126. doi: 10.1016/j.bbagen.2011.09.004. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

51. Brumpton B. M., Camargo C. A., Romundstad P. R., Langhammer A., Chen Y. , Mai X.-M. Metabolic syndrome and incidence of asthma in adults: the HUNT study. European Respiratory Journal. 2013;42(6):1495–1502. doi: 10.1183/09031936.00046013. [PubMed] [CrossRef] [Google Scholar]

52. Cottrell L., Neal W. A., Ice C., Perez M. K., Piedimonte G. Metabolic abnormalities in children with asthma. American Journal of Respiratory and Critical Care Medicine. 2011;183(4):441–448. doi: 10.1164/rccm.201004-0603oc. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

53. Klein O. L., Krishnan J. A., Glick S., Smith L. J. Systematic review of the association between lung function and Type 2 diabetes mellitus. Diabetic Medicine. 2010;27(9):977–987. doi: 10.1111/j.1464-5491.2010.03073.x. [PubMed] [CrossRef] [Google Scholar]

54. Aronson D. Hyperglycemia and the pathobiology of diabetic complications. Advances in Cardiology. 2008;45:1–16. doi: 10.1159/000115118. [PubMed] [CrossRef] [Google Scholar]

55. Yu D., Simmons D. Association between lung capacity measurements and abnormal glucose metabolism: findings from the Crossroads study. Diabetic Medicine. 2014;31(5):595–599. doi: 10.1111/dme.12346. [PubMed] [CrossRef] [Google Scholar]

56. O’Byrne P. M., Rennard S., Gerstein H., Radner F., Peterson S., Lindberg B. Risk of new onset diabetes mellitus in patients with asthma or COPD taking inhaled corticosteroids. Respiratory Medicine. 2012;106:1487–1493. [PubMed] [Google Scholar]

57. Katsuyama T., Sada K.-E., Namba S., et al. Risk factors for the development of glucocorticoid-induced diabetes mellitus. Diabetes Research and Clinical Practice. 2015;108(2):273–279. doi: 10.1016/j.diabres.2015.02.010. [PubMed] [CrossRef] [Google Scholar]

58. Van Raalte D. H., Ouwens D. M., Diamant M. Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options? European Journal of Clinical Investigation. 2009;39(2):81–93. doi: 10.1111/j.1365-2362.2008.02067.x. [PubMed] [CrossRef] [Google Scholar]

59. Slatore C. G., Bryson C. L., Au D. H. The association of inhaled corticosteroid use with serum glucose concentration in a large cohort. The American Journal of Medicine. 2009;122(5):472–478. doi: 10.1016/j.amjmed.2008.09.048. [PubMed] [CrossRef] [Google Scholar]

60. Regateiro F., Moura A. L., Faria E. Novos biológicos para o tratamento da asma. Revista Portuguesa de Imunoalergologia. 2017;25:99–113. [Google Scholar]

61. Yalcin A. D., Gorczynski R. M., Cilli A., Strauss L. Omalizumab (anti-IgE) therapy increases blood glucose levels in severe persisten tallergic asthma patients with diabetes mellitus: 18-month follow-up. Clinical Laboratory. 2014;60:1561–1564. doi: 10.7754/clin.lab.2013.130302. [PubMed] [CrossRef] [Google Scholar]

62. Hamada S., Kuroe A., Tsukino M. Does omalizumab impair glucose homeostasis in a patient with severe persistent asthma and type 2 diabetes mellitus? Revista Portuguesa de Pneumologia (English Edition) 2017;23(5):303–304. doi: 10.1016/j.rppnen.2017.05.002. [PubMed] [CrossRef] [Google Scholar]

63. Ferreira L., Moniz A. C., Carneiro A. S., et al. The impact of glycemic variability on length of stay and mortality in diabetic patients admitted with community-acquired pneumonia or chronic obstructive pulmonary disease. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2019;13(1):149–153. doi: 10.1016/j.dsx.2018.08.028. [PubMed] [CrossRef] [Google Scholar]

64. Xia C., Rao X., Zhong J. Role of T Lymphocytes in type 2 diabetes and diabetes-associated inflammation. Journal of Diabetes Research. 2017;2017:6. doi: 10.1155/2017/6494795.6494795 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

65. Black M. H., Anderson A., Bell R. A., et al. Prevalence of asthma and its association with glycemic control among youth with diabetes. Pediatrics. 2011;128(4):e839–e847. doi: 10.1542/peds.2010-3636. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

66. Rogliani P., Calzetta L., Capuani B., et al. Glucagon-like peptide 1 receptor: a novel pharmacological target for treating human bronchial hyperresponsiveness. American Journal of Respiratory Cell and Molecular Biology. 2016;55(6):804–814. doi: 10.1165/rcmb.2015-0311oc. [PubMed] [CrossRef] [Google Scholar]

67. Mitchell P. D., Salter B. M., Oliveria J. P., et al. Glucagon-like peptide-1 receptor expression on human eosinophils and its regulation of eosinophil activation. Clinical & Experimental Allergy. 2017;47(3):331–338. doi: 10.1111/cea.12860. [PubMed] [CrossRef] [Google Scholar]

68. Barros L. L., Souza-Machado A., Corrêa L. B., et al. Obesity and poor asthma control in patients with severe asthma. Journal of Asthma. 2011;48(2):171–176. doi: 10.3109/02770903.2011.554940. [PubMed] [CrossRef] [Google Scholar]

69. Forno E., Zhang P., Nouraie M., Courcoulas A., Mitchell J. E., Wolfe B. The impact of bariatric surgery on asthma control differs among obese individuals with reported prior or current asthma, with or without metabolic syndrome. PLoS One. 2019;14(4) doi: 10.1371/journal.pone.0214730.e0214730 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

The combination of bronchial asthma and diabetes: synergism or antagonism? | Ivanov

1. Lowder T.W., Kunz H.E. Regulatory T cells in asthma and airway hyperresponsiveness. J. Allergy Ther. 2011; Suppl. 1:1–8.

2. Karlstad O., Nafstad P., Tverdal A. et al. Comorbidities in an asthma population 8–29 years old: a study from the Norwegian Prescription Database. Pharmacoepidemiol. drug. Saf. 2012; 21:1045–1052.

3. Shi H.N., Walker W.A. T helper cell subclasses and clinical disease states. Curr. Opin. Gastroenterol. 2002; 18:711–716.

4. Mineev V.N. The concept of bronchial asthma as a membrane-receptor pathology. Immunopathology, allergology, infectology. 2005; 3:68–85. / Mineev V.N. An approach to bronchial asthma as to membrane and receptor pathology. Immunopathology, allergology, infektologiya. 2005; 3: 68–85 (in Russian).

5. Vianna E.O., Garcia-Leme J. Allergen-induced airway inflammation in rats. Role of insulin. Am. J. Respir. Crit. care. Med. 1995; 151:809–814.

6. Insuela D.B.R., Silva P.M.R., Martins M.A., Carvalho V.F. The Yin Yang of hormones that control glucose homeostasis in asthma. J. Allergy Ther. 2013; 11:3–8.

7. Kolychev A.P., Mineev V.N., Bulatova N.Yu., Fedoseev G.B. Features of insulin-receptor interactions in bronchial asthma. Pulmonology. 1994; 2:48–51. / Kolychev A.P., Mineev V.N., Bulatova N.Yu., Fedoseev G.B. Insulin-receptor interactions in bronchial asthma. Pul’monologia. 1994; 2: 48–51 (in Russian).

8. Hashemzadeh M., Movahed M.R. The occurrence of asthma in hospitalized patients with type 2 diabetes mellitus. Intern. Med. J. 2009; 39(10): 699–701.

9. Sheiner E., Mazor M., Levy A. et al. Pregnancy outcome of asthmatic patients: a population-based study. J. Matern. Fetal neonate. Med. 2005; 18:237–40.

10. Rapaport M.J., Bistritzer T. , Aharoni D. Th2/Th3 cytokine secretion of first degree relatives of T1DM patients. Cytokine. 2005; 30(5): 219–227.

11. Kononenko I.V., Prokofiev S.A., Smirnova O.M. The functional state of β-cells, immunological and clinical and biochemical characteristics in patients with slowly progressive autoimmune diabetes in adults. Problems of endocrinology. 2004; 50(1): 18–22. / Kononenko I.V., Prokof’ev S.A., Smirnova O.M. Functional status of β-cells and immunological, clinical and biochemical features of adult patients with slowly-progressive autoimmune diabetes mellitus. Problemy endocrinology. 2004; 50 (1): 18–22 (in Russian).

12. Saprina T.V., Lazarenko F.E., Prokhorenko T.S. The role of Th2/Th3 imbalance of the immune response in determining the clinical features of autoimmune diabetes mellitus in adults. Diabetes. 2011; 2:12–17. / Saprina T.V., Lazarenko F.E., Prokhorenko T.S. et al. A role of Th2/Th3 immune imbalance for clinical course of diabetes mellitus in adults. Sakharny diabetes. 2011; 2:12–17 (in Russian).

13. Brealey D., Singer M. Hyperglycemia in critical illness: a review. J. Diabetes. sci. Technol. 2009; 3:1250–1260.

14. McMahon G.T., Arky R.A. Inhaled insulin for diabetes mellitus. N. Engl. J. Med. 2007; 356:497–502.

15. Mineev V.N., Bulatova N.Yu. Features of the influence of glucose inhalations on bronchial reactivity in bronchial asthma. Clinical medicine. 2001; 79(8):37–39. / Mineev V.N., Bulatova N.Yu. An influence of inhalational glucose on bronchial reactivity in patients with asthma. Clinical Meditsina. 2001; 79 (8): 37–39 (in Russian).

16. Viardot A., Gray S.T., Mackay F., Chisholm D. Potential antiinflammatory role of insulin via the preferential polarization of effector T cells towards a T helper 2 phenotype. endocrinology. 2007; 148:346–353.

17. Shore S.A., Schwartzman I.N., Mellema M.S. et al. Effect of leptin on allergic airway responses in mice. J. Allergy Clin. Immunol. 2005; 115:103–109.

18. Giannessi D., Maltinti M., Del Ry S. Adiponectin circulating levels: a new emerging biomarker of cardiovascular risk. Pharmacol. Res. 2007; 56:459–467.

19. Shore S.A., Terry R.D., Flynt L. et al. Adiponectin attenuates allergen-induced airway inflammation and hyperresponsiveness in mice. J. Allergy Clin. Immunol. 2006; 118:389–395.

20. Sherman M.S., Lazar E.J., Eichacker P. A bronchodilator action of glucagon. J. Allergy. Clin. Immunol. 1988; 81:908–911.

21. Imbruce R., Goldfedder A., ​​Maguire W. et al. The effect of glucagon on airway resistance. J.Clin. Pharmacol. 1975; 15:680–684.

22. Olsen P.C., Coelho L.P., Costa J.C. et al. Two for one: cyclic AMP mediates the anti-inflammatory and anti-spasmodic properties of the non-anesthetic lidocaine analog JMF2-1. Eur. J Pharmacol. 2012; 680:102–107.

23. Hu C.P., Zou Y.Q., Feng J.T., Li X.Z. The effect of unilateral adrenalectomy on transformation of adrenal medullary chromaffin cells in vivo: a potential mechanism of asthma pathogenesis. PLOS One. 2012; 7:e44586.

24. Scola A.M., Loxham M., Charlton S.J., Peachell P.T. The long-acting beta-adrenoceptor agonist, indacaterol, inhibits IgE-dependent responses of human lung mast cells. Br. J Pharmacol. 2009; 158:267–276.

25. Goleva E., Dunlap A., Leung D.Y. Differential control of Th2 versus Th3 cell responses by the combination of lowdose steroids with beta2-adrenergic agonists. J. Allergy Clin. Immunol. 2004; 114:183–191.

26. Giordano R., Guaraldi F., Berardelli R. et al. Glucose metabolism in patients with subclinical Cushing’s syndrome. endocrine. 2012; 41:415–423.

27. Torres R.C., Insuela D.B.R., Carvalho V.F. Mecanismos celulares e moleculares da acao antiinflamatoria dos glicocorticoides. Corpus et Scientia. 2012; 8:36–51.

28. Maneechotesuwan K., Yao X., Ito K. et al. Suppression of GATA-3 nuclear import and phosphorylation: a novel mechanism of corticosteroid action in allergic disease. PLOS Med. 2009; 6: e1000076.

29. Ammit A.J., Burgess J.K., Hirst S.J. et al. The effect of asthma therapeutics on signaling and transcriptional regulation of airway smooth muscle function. Pulm. Pharmacol. Ther. 2009; 22:446–454.

30 Barnes P.J. Biochemical basis of asthma therapy. J Biol. Chem. 2011; 286:32899–32905.

31. Rajala M.W., Obici S., Scherer P.E., Rossetti L. Adiposederived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production. J.Clin. Invest. 2003; 111:225–230.

32. Condliffe A.M., Cadwallader K.A., Walker T.R. et al. Phosphoinositide 3-kinase: a critical signaling event in pulmonary cells. Respir. Res. 2000; 1:24–29.

33. Fedoseev G.B., Trofimov V.I., Petrova M.A., red. Many-sided bronchial asthma, diagnosis, treatment and prevention. St. Petersburg: Nordmed-Izdat; 2011. / Fedoseev G.B., Trofimov V.I., Petrova M.A., eds. Multifaceted Bronchial Asthma: Diagnosis, Treatment, Prevention. St. Petersburg: Nordmed-Izdat; 2011 (in Russian).

Bronchial asthma and diabetes mellitus

Bronchial asthma and diabetes mellitus occur against the background of impaired functioning of the immune system. Diabetes mellitus develops as an autoimmune disease with the production of antibodies against the pancreas’ own cells. In bronchial asthma, plant pollen, food, animal hair, bacteria, etc. act as an antigen. The risk of developing asthma in diabetics is higher than in people without autoimmune diseases.

There is also a risk of impaired carbohydrate metabolism for asthmatics using glucocorticosteroids for treatment. With this combination, the development of diabetes as a complication of steroid therapy is less common than osteoporosis or other side effects, but all steroids and a number of other drugs used to treat bronchial asthma worsen the course of existing diabetes, as they increase blood sugar levels.

Patients with asthma who are diagnosed with steroid diabetes usually have severe asthma, which is the reason for the prescription of systemic steroids. Their use in high doses or for a long time leads to obesity. Obesity, in turn, worsens the course of diabetes.

Bronchial asthma in diabetes mellitus occurs more often in the first, insulin-dependent type. There was no association between type 2 diabetes and the incidence of asthma.

For patients with bronchial asthma, a complete cessation of smoking is necessary, since this factor leads to frequent attacks of suffocation and causes circulatory disorders, vasospasm. In diabetes mellitus, in conditions of angiopathy, smoking increases the risk of developing diabetic neuropathy, heart disease, destruction of the glomeruli of the kidneys and kidney failure.

In order to prevent complications of diabetes in the treatment of bronchial asthma, patients are recommended to:

1. Constant monitoring of blood sugar levels and dose adjustment while prescribing glucocorticoids.

2. Follow a diet that limits simple carbohydrates and foods that can cause allergic reactions.